Skip to main content
Premium Trial:

Request an Annual Quote

HDL to Offer BG's Heart Failure Test as Service

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Health Diagnostic Laboratory today said that it has signed an agreement to offer BG Medicine's galectin-3 test as a service to physicians.

The Richmond, Va.-based health management and biomarker-based testing firm, said that it will provide the BG test, which was cleared for marketing by the US Food and Drug Administration in late 2010, to physicians along with its own cardiovascular tests. The test is used as an aid in assessing the prognosis of patients with chronic heart failure.

Financial and other terms of the alliance were not disclosed.

BG's marketing partner, Laboratory Corporation of America, began selling the test in the US in January.